行业担忧 - 慢性病患者可能面临通过正规渠道难以购买原研药的困境 [1] - 对国产药的上市流程和安全性持观望态度，至少需要 5-10 年的观察期 [1] 应对措施 - 寻求原研药和进口药的走私渠道 [1] - 呼吁分享应对措施和经验 [1]

Core Insights - The event "High-Quality Development of Domestic Pharmaceuticals" was held at Qilu Pharmaceutical Group, aimed at showcasing the true quality of domestic drugs and the achievements of China's manufacturing industry [1][3] - A seminar was conducted where industry experts and media representatives discussed the challenges and opportunities in the high-quality development of domestic pharmaceuticals [3][5] Group 1: Industry Overview - The event was organized by the China Pharmaceutical News Information Association, focusing on quality management systems, R&D innovation platforms, and intelligent manufacturing bases [1] - Experts emphasized the need for strong promotion and scientific communication to enhance the brand image of domestic pharmaceuticals, highlighting their quality, international standing, and contributions to public health [3] Group 2: Company Insights - Qilu Pharmaceutical, as a leading domestic pharmaceutical company, shared its experiences in innovation, smart manufacturing, and international quality system construction [3][5] - The company has over 300 products on the market, with more than 70 being the first or exclusive in China, significantly reducing the economic burden on the national healthcare system [7][9] Group 3: R&D and Innovation - Qilu Pharmaceutical is actively developing over 80 innovative drug projects, with two national class I new drugs already launched [9] - The company has established six R&D centers in the U.S. and is focused on high-end new formulations, achieving breakthroughs in various advanced drug delivery systems [9] Group 4: Market Position and Strategy - Qilu Pharmaceutical has a leading market share in domestic clinical prescriptions and is expanding its presence in international markets, with nearly 40 formulation products in regions like the U.S., EU, Japan, and Australia [7][9] - The company has won bids for 100 drugs under the national drug procurement policy, significantly lowering drug prices to benefit the public [9]